Go Pro
NASDAQ:CARL

Carlsmed (CARL) Stock Price, News & Analysis

Carlsmed logo
$14.27 +0.51 (+3.71%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$14.28 +0.02 (+0.11%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Carlsmed Stock (NASDAQ:CARL)

Advanced

Key Stats

Today's Range
$13.70
▼
$14.61
50-Day Range
$11.45
▼
$16.88
52-Week Range
$8.50
▼
$17.23
Volume
151,613 shs
Average Volume
73,068 shs
Market Capitalization
$389.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.25
Consensus Rating
Moderate Buy

Company Overview

Carlsmed, Inc. is a medical technology company focused on improving outcomes for patients undergoing complex spinal surgery. The company develops personalized implants and surgical solutions designed to help spine surgeons address the anatomical needs of individual patients, particularly those with adult spinal deformity and other challenging spinal conditions.

Its principal product platform, aprevo, uses patient-specific planning and implant design to support spinal reconstruction procedures. The platform includes customized interbody and posterior implants that are manufactured using three-dimensional printing and are intended to help surgeons restore spinal alignment and achieve their procedural objectives.

Carlsmed was founded in 2015 and is headquartered in Carlsbad, California. The company primarily serves spine surgeons, hospitals and patients in the United States, with its products used in specialized spinal procedures. Carlsmed works with healthcare providers to incorporate patient-specific imaging, surgical planning and customized implants into the treatment process.

AI Generated. May Contain Errors.

Carlsmed Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

CARL MarketRank™: 

Carlsmed scored higher than 43% of companies evaluated by MarketBeat, and ranked 594th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Carlsmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Carlsmed has a consensus price target of $19.25, representing about 34.9% upside from its current price of $14.27.

  • Amount of Analyst Coverage

    Carlsmed has only been the subject of 3 research reports in the past 90 days.

  • Read more about Carlsmed's stock forecast and price target.
  • Earnings Growth

    Earnings for Carlsmed are expected to decrease in the coming year, from ($1.50) to ($1.53) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Carlsmed is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Carlsmed is -9.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Carlsmed has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.54% of the float of Carlsmed has been sold short.
  • Short Interest Ratio / Days to Cover

    Carlsmed has a short interest ratio ("days to cover") of 12.98, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Carlsmed has recently decreased by 1.98%, indicating that investor sentiment is improving.
  • Dividend Yield

    Carlsmed does not currently pay a dividend.

  • Dividend Growth

    Carlsmed does not have a long track record of dividend growth.

  • News Sentiment

    Carlsmed has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Carlsmed this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for CARL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Carlsmed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Carlsmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,400.00 in company stock.

  • Percentage Held by Insiders

    12.90% of the stock of Carlsmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Carlsmed has minimal institutional ownership at this time.

  • Read more about Carlsmed's insider trading history.
Receive CARL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carlsmed and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CARL Stock News Headlines

Carlsmed names new CFO, reaffirms 2026 revenue view
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
Carlsmed names new CFO
Carlsmed Names Richard Heppenstall as CFO
Carlsmed, Inc. Announces CFO Changes
See More Headlines

CARL Stock Analysis - Frequently Asked Questions

Carlsmed's stock was trading at $12.35 at the start of the year. Since then, CARL shares have increased by 15.5% and is now trading at $14.27.

Carlsmed, Inc. (NASDAQ:CARL) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The business earned $18.94 million during the quarter. Carlsmed had a negative trailing twelve-month return on equity of 38.06% and a negative net margin of 57.42%.
Read the conference call transcript
.

Carlsmed (CARL) raised $100 million in an initial public offering (IPO) on Wednesday, July 23rd 2025. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share.

Shares of CARL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/05/2026
Today
10/03/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:CARL
CIK
1794546
Fax
N/A
Employees
127
Year Founded
2018

Price Target and Rating

High Price Target
$23.00
Low Price Target
$17.00
Potential Upside/Downside
+34.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.63 million
Net Margins
-57.42%
Pretax Margin
-57.42%
Return on Equity
-38.06%
Return on Assets
-28.96%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
8.84
Quick Ratio
8.66

Sales & Book Value

Annual Sales
$50.51 million
Price / Sales
7.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.72 per share
Price / Book
3.84

Miscellaneous

Outstanding Shares
27,300,000
Free Float
23,781,000
Market Cap
$389.57 million
Optionable
N/A
Beta
2.09

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:CARL) was last updated on 10/3/2026 by MarketBeat.com Staff.
From Our Partners